BRAF and thyroid gland papillary carcinoma: Immunohistochemical (IHC) detection of BRAF V600E with a mutation specific antibody (clone VE1) was first described in metastatic melanoma and papillary thyroid carcinoma (11), and the antibody is currently commercially available (Figures 1A,B).